AZN — ASTRAZENECA PLC

—
NYSE · Health Care · Pharmaceuticals · CIK 901832 · United Kingdom
Last close
$182.27
Market Cap
$282.68B
52W High
$210.52
52W Low
$153.41
ADV30
2,998,812
Next earnings
2026-10-30

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 16,209,000,000 13,263,000,000 4,387,000,000 3,117,000,000 119,922,000,000 7,936,000,000 68,108,000,000
Jun 2026 15,384,000,000 12,861,000,000 3,164,000,000 2,507,000,000 115,833,000,000 4,893,000,000 65,463,000,000
Mar 2026 15,288,000,000 12,610,000,000 4,246,000,000 3,080,000,000 114,015,000,000 7,560,000,000 66,631,000,000
Dec 2025 15,503,000,000 12,385,000,000 2,978,000,000 2,326,000,000 114,074,000,000 5,711,000,000 65,355,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$13,232,000,000
Investing CF
$-8,035,000,000
Financing CF
$-5,348,000,000
CapEx
$-7,135,000,000
Dividends Paid
$-4,958,000,000
Buybacks
—
EPS Diluted TTM
$7.07
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$14,069,000,000
Inventory
$6,883,000,000
Receivables
—
ST Investments
$230,000,000
EBIT TTM
$15,089,000,000
Pretax Income TTM
$13,300,000,000
Interest Exp TTM
$1,789,000,000
Analysts
12

Yahoo Snapshot (yfinance, live)

Total Revenue
$61,366,001,664
EBITDA
$19,904,000,000
Free Cash Flow
$4,905,375,232
Enterprise Value
$275,880,673,280
Total Cash
$4,968,000,000
Total Debt
$32,349,999,104
Shares Out
1,550,895,914
Trailing EPS
$6.68
Book Value
$32.43
ROE
22.0%
ROA
8.0%
Div Yield
2.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 58,739,000,000 13,327,000,000 10,225,000,000 114,074,000,000 65,355,000,000 48,667,000,000 14,575,000,000
Dec 2024 54,073,000,000 10,251,000,000 7,035,000,000 104,035,000,000 63,164,000,000 40,786,000,000 11,861,000,000
Dec 2023 45,811,000,000 8,722,000,000 5,955,000,000 101,119,000,000 61,953,000,000 39,143,000,000 10,345,000,000
Dec 2022 44,351,000,000 4,512,000,000 3,288,000,000 96,483,000,000 59,425,000,000 37,037,000,000 9,808,000,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$11.36

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $165.00 · spot: $178.76 · call volume: 420 · put volume: 494
Expected Move to 2027-01-15: ±$15.30 (8.56%) — implied range $163.46 – $194.06 · ATM straddle on $180.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
NVS NOVARTIS AG $302.46B $159.13 —
MRK Merck & Co., Inc. $353.44B $143.37 —
ABT ABBOTT LABORATORIES $181.35B $104.71 —
PFE PFIZER INC $162.27B $28.47 —
ABBV AbbVie Inc. $517.59B $292.82 —

News headlines (Yahoo Finance, 1h cache)

AstraZeneca gets Jefferies backing as broker sees $80bn sales target within reach
2026-11-18 15:30 · Yahoo
The Zacks Analyst Blog Highlights AstraZeneca, Linde, Eaton, Franklin and BV Financial
2026-11-18 10:43 · Yahoo
AstraZeneca Stock Up 12% in a Month: Time to Buy, Sell or Hold?
2026-11-17 14:58 · Yahoo
AstraZeneca Bet $2 Billion on Summit’s Cancer Drug. The FDA Just Said Not Yet.
2026-11-16 16:37 · Yahoo
AstraZeneca Secures US, EU Nod for New Myasthenia Gravis Drug Klygefa
2026-11-16 16:02 · Yahoo
Is AstraZeneca (LSE:AZN) Reasonable After Its Oncology Led Cash Flow Push?
2026-11-14 01:11 · Yahoo
AstraZeneca (LSE:AZN) Will Transfer Its Primary Listing To The NYSE In 2026
2026-11-14 00:24 · Yahoo
Summit Therapeutics (SMMT) Stock Sees Modest Fair Value Cut As Analysts Weigh Trial Risks
2026-11-17 11:14 · Yahoo
Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene Editing ...
2026-11-13 23:03 · Yahoo
FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK
2026-11-18 14:21 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.